David Greenwald is a partner in Cravath, Swaine & Moore’s litigation department. He practises general commercial litigation, with a concentration on patent litigation (particularly concerning chemical, pharmaceutical and biotechnological patents) and white collar criminal defence. Mr Greenwald is a patent attorney registered with the US Patent and Trademark Office.
Mr Greenwald’s representative patent matters have included:
- representation in patent litigation under the Biologics Price Competition and Innovation Act of the first biological drug company to obtain approval to market a biosimilar of Humira®, the world’s best-selling drug;
- representation at trial of a major pharmaceutical company in Hatch-Waxman Act actions to enjoin approval of generic versions of Posaconazole, a drug indicated for the prevention of life-threatening fungal infections;
- representation at trial of a pharmaceutical company in an action to enforce patents covering formulations of a long-acting beta-adrenergic agonist indicated for the treatment of chronic obstructive pulmonary disease and bronchitis;
- representation at trial of a pharmaceutical company in a federal action to enforce a patent covering the most widely prescribed prescription anti-coagulant drug;
- representation of a pharmaceutical company in an appeal from an adverse judgment enjoining generic entry of a drug indicated for the treatment of AIDS;
- representation before federal district courts of various other pharmaceutical companies in actions to enjoin approval and marketing of generic versions of patented drugs;
- representation of a major biotechnology company in an action asserting infringement of a patent claiming improved methods for expressing proteins in mammalian cells;
- representation of a drug company in an action to enforce a patent claiming methods of inhibiting NF-kB, a major cellular signalling molecule; and
- defence of a chemical company against claims of patent infringement relating to fluoropolymer emulsification technology.
Mr Greenwald received a bachelor’s, summa cum laude, in biochemical sciences from Harvard College in 1990 and a JD, with high honours, from the University of Chicago in 1993.
Register for more free content
- Read more IAM blogs and articles
- Receive the editor's weekly review by email